RGC
Regencell Bioscience Holdings Ltd.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · HK
$6.71
−2.19%Price chart
Oct 1Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30
Key dataOct 30, 2026
Open$6.74
From 52W high−87.31%
Volume147228.00
Market cap$3.33B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 30, 2026
Open
$6.74
From 52W high
−87.31%
Volume
147228.00
Market cap
$3.33B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−292.7x
P/E (TTM)
—
RSI (14)
43.9
MomentumView details →
1D Return
−2.19%
YTD Return
−67.24%
SummaryUpdated Jun 1, 2026
Regencell Bioscience Holdings Limited (NASDAQ:RGC) is a Traditional Chinese Medicine (TCM) bioscience company founded in 2014 and headquartered in Causeway Bay, Hong Kong. The company went public on July 16, 2021, and focuses on developing innovative treatments for neurocognitive disorders using traditional Chinese medicine principles combined with modern scientific research methods. Regencell is currently in the research and development phase, with no commercial products yet generating revenue.
Similar companies
Latest newsMore news →
No recent news for RGC.